US Medical Plastics Shake-Up: Imports Overwhelm Domestic Products as Tariffs Become a Double-Edged Sword

As a key driver of plastic demand, the U.S. medical devices and consumables industry has experienced significant production fluctuations in recent years due to the COVID-19 pandemic, post-pandemic inventory adjustments, and shifts in global trade dynamics. Although U.S. healthcare spending remains robust—reaching $2.9 trillion in 2025—domestic production continues to face multiple challenges, including import competition and financial pressures on healthcare providers.

Dr. Perc Pineda, Chief Economist of the Plastics Industry Association, noted in a blog post that the aforementioned trends have created a complex development environment for the plastics industry, while plastics play an indispensable role in the manufacturing and packaging of medical products. Industry experts are now conducting in-depth analysis of how these changes will impact the future applications of plastics in the medical field.

Measured by the Industrial Production Index (IPI), the output of medical equipment and supplies in the United States surged significantly during the pandemic, reaching 31.5% higher than the 2017 level in July 2021, hitting a peak. However, as demand returned to normal and inventory entered an adjustment phase, production began to decline. By February 2026, it had fallen 15.7% from its peak in October 2023. This sharp fluctuation highlights the opportunities and challenges faced by the plastic industry, as plastic remains a critical material for the production of key medical products such as syringes, catheters, and surgical instruments.

Pineda explained, "Following a 2.1% decline in production in May 2023, the industry saw consecutive monthly gains, with output in October 2023 standing 5.4% above the 2017 baseline level; however, production has since retreated from this recent peak, posting a cumulative decline of 15.7% as of February 2026."

U.S. healthcare spending has long remained at a high level. Since 2007, its share of personal consumption expenditures (PCE) after adjusting for inflation has consistently been between 16% and 17%. In 2025, U.S. healthcare spending is expected to reach $2.9 trillion, accounting for 18% of personal consumption expenditure. This stable demand further underscores the importance of plastics in the medical field. Pineda noted, "Since 2007, spending on pharmaceuticals and other medical products containing plastics and packaging has consistently made up 3% to 4% of actual personal consumption, reaching $663.2 billion in 2026." Plastics are widely used in syringes, catheters, surgical instruments, and various medical packaging materials.

Inventory Adjustment After the Pandemic

The Federal Reserve Board of the United States tracks an industrial production index for medical devices and supplies, covering products under NAICS (North American Industry Classification System) category 3391, which includes companies manufacturing medical devices for healthcare facilities. Pineda stated, "Plastics are extensively used in this sector, encompassing diagnostic equipment, laboratory instruments, syringes, catheters, and related disposable items, as well as surgical instruments, dental equipment, ophthalmic supplies, orthopedic devices, prosthetics, and artificial organs."

However, the prolonged high growth of medical equipment and consumables production after the pandemic has triggered inventory adjustments. The plastic manufacturing sector under NAICS code 3261 has experienced a shorter period of high-capacity operation, which has to some extent buffered the impact of the decline in medical plastic demand. The process of digesting pandemic-related high inventory has hindered production in the NAICS code 3391 category, indirectly affecting the demand for plastics.

Import Competition and Tariff Impact

Despite higher tariffs on certain imported products, overseas medical devices and components continue to replace U.S.-made alternatives. Pineda emphasized that, even under the impact of Section 232 steel and aluminum tariffs, U.S. imports of medical devices and supplies remained stable in 2025. Products with metal casings or metal components—such as diagnostic and surgical instruments—are directly affected by these tariff measures.

In contrast, personal protective equipment, masks, hoses, instrument components, and packaging materials, which are plastic consumables, are not subject to the tariffs derived from Section 232. This exemption policy has effectively stabilized the demand for plastics in this specific sector.

Pineda said: "Whether domestic production can recover depends on how long the low volume of elective surgeries continues, a trend that has been noted by industry observers in 2023. Financial market analyses also point out that hospitals are facing financial pressures and cost control challenges, which in turn affect their capital equipment purchasing decisions. Future interest rate cuts may alleviate further delays in such purchases, providing support for local production."

Macroeconomic Outlook

KPMG, a New York-headquartered audit, tax, and advisory firm, forecasts that the global medical device industry will maintain steady growth, with an annual growth rate exceeding 5%, and global sales projected to reach nearly $800 billion by 2030.

Josh Hirt, Senior U.S. Economist at Vanguard, an investment management firm headquartered in Valley Forge, Pennsylvania, stated in a report this month that the U.S. economic outlook is positive, with growth momentum driven by robust business investment, resilient consumer demand, and substantial AI-related capital expenditures. Supported by domestic private demand, U.S. real GDP is expected to grow at a moderate pace of around 2%.

Although Vanguard’s March U.S. employment report indicates a slight softening in the labor market, it remains broadly stable overall. Employment growth in the healthcare sector continues to stand out as a structural highlight, and the annual unemployment rate is expected to remain steady. Current labor market risks stem more from the transformative impact of rapidly advancing artificial intelligence technologies than from an economic recession, and the market is likely to remain stable in the near term.

Services inflation remains elevated, driven by steadily rising wages, although overall inflationary pressures have eased slightly. Hirt noted that tariff exemptions and related legal constraints have reduced the pass-through effect of tariffs, leading to a greater-than-expected alleviation of trade-related inflationary pressures.

Hirt added, "We continue to monitor the crude oil market and developments in the Middle East, which could push up inflation or disrupt financial conditions."

S&P Global Energy data shows that, under an extreme “oil shock” scenario, the U.S. economy would perform significantly worse than current expectations.

S&P Global reported: “The central assumption of this scenario is that the Strait of Hormuz remains under de facto blockade throughout April, hindering the resumption of production at oil fields and refineries, thereby triggering supply shortages and a sharp rise in oil prices. The Brent crude spot monthly average price is projected to peak at $200 per barrel in the second quarter of 2026 and remain above $100 per barrel by year-end.”

Strategic Outlook for the Plastics Industry

Looking ahead, the U.S. medical device and supplies supply side is showing a divergent trend: imports remain stable, while domestic production has somewhat declined; however, industry demand remains solid, supported by sustained healthcare spending. Pineda emphasizes the need to focus on the global value chain of medical device and supplies manufacturing to assess the sector’s long-term growth prospects.

Pineda summarized: "This imbalance between supply and demand is reflected in the price level: the Producer Price Index (PPI) for medical equipment and consumables manufacturing showed a downward trend from February to August 2025, then turned to a year-on-year increase from September 2025 to February 2026. However, the index showed a slight decline in January-February 2026, with the year-on-year growth rate dropping from 3.1% in December 2025 to 2.9%."

As the industry gradually returns to normal after the pandemic, completes inventory adjustments, and deals with import competition, the plastics industry will remain a core support for the production and packaging of medical devices and supplies. Formulating strategic plans and adapting to dynamic market changes are key to achieving sustained growth in this critical sector.